Duchenne Muscular Dystrophy Drugs Industry Outlook 2025-2029: Market Set to Cross $5.31 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Duchenne Muscular Dystrophy Drugs Market Size By 2025?
The market size for drugs treating Duchenne muscular dystrophy has experienced swift expansion in the past few years. The market, which is expected to have a value of $2.83 billion in 2024, is estimated to reach $3.2 billion by 2025, representing a compound annual growth rate (CAGR) of 13.2%. The historical growth can be credited to factors such as enhanced diagnostic capabilities, the increase in patient registries and data collection, a surge in demand, an expanding array of clinical-stage therapies in the pipeline, and the growth of regulatory incentives.

How Big Is the Duchenne Muscular Dystrophy Drugs Market Size Expected to Grow by 2029?
The market for Duchenne muscular dystrophy drugs is anticipated to experience remarkable expansion in the forthcoming years, going up to $5.31 billion in 2029 with a compound annual growth rate of 13.4%. Several factors could account for this surge in the projected period including the proliferation of early-phase biotech firms, an increase in empirical evidence after marketing, a rise in spending on healthcare, an escalating call for early treatment methods, and enlarging use of off-label corticosteroids. Influential trends to anticipate during the forecast span incorporate increasing biotech creativity, the merging of digital health & wearable tech, an upsurge in the interest for personalised and mutation-specific therapies, as well as advancements in gene therapy and CRISPR.

View the full report here:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-drugs-global-market-report

Which Key Market Drivers Powering Duchenne Muscular Dystrophy Drugs Market Expansion and Growth?
The surge in Duchenne muscular dystrophy (DMD) drugs market is anticipated to be fueled by developments in personalized medicine. This specific branch of medical science caters to the unique genetic, environmental, and lifestyle traits of an individual to deliver optimized healthcare outcomes. The progress in genomic technologies has led to a rise in demand for personalized medicine as it lets us accurately identify genetic differences and provides individually-adjusted treatments. This kind of medical approach significantly aids the Duchenne muscular dystrophy (DMD) drugs market by providing therapies that cater to individual genetic profiles, thus increasing the treatment's effectiveness. It contributes to drug development by targeting particular genetic modifications, which improve treatment results and overall healthcare quality. For example, the U.S. FDA sanctioned 26 novel personalized medicines in 2023, marking a substantial ascent from the 12 approvals in the previous year, as reported by the US-based nonprofit organization, the Personalized Medicine Coalition (PMC), in February 2024. Hence, the advancements in personalized medicine are instrumental in driving the Duchenne muscular dystrophy (DMD) drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24213&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Duchenne Muscular Dystrophy Drugs Market?
Leading firms in the Duchenne muscular dystrophy (DMD) drugs market are prioritizing the development of innovative treatments such as corticosteroids, with an aim to boost muscle strength, slow down the progression of the disease, and improve the overall results for patients. Corticosteroids, either naturally produced in the adrenal glands or created as medicines, are used to reduce inflammation and restrain the immune system. For example, Catalyst Pharmaceuticals, a biopharmaceutical company based in the US, introduced AGAMREE (vamorolone) oral suspension 40 mg/mL in March 2024. This treatment, approved by the Food and Drug Administration (FDA), is designed for Duchenne muscular dystrophy patients aged two and above. AGAMREE is a corticosteroid that functions by lessening inflammation and fortifying muscle cell membranes, which aids in slowing the disease's advancement.

What Are the Emerging Segments in the Duchenne Muscular Dystrophy Drugs Market?
The duchenne muscular dystrophy drugs market covered in this report is segmented -

1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24213&type=smp

Who Are the Global Leaders in the Duchenne Muscular Dystrophy Drugs Market?
Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.

Which are the Top Profitable Regional Markets for the Duchenne Muscular Dystrophy Drugs Industry?
North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24213

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Reach out to us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

The Business Research Company, with over 17,500+ reports across 27 industries and 60+ geographies, backed by 1,500,000 datasets and insights from industry leaders, offers comprehensive market intelligence through its flagship product, the Global Market Model (GMM), delivering updated forecasts for informed decision-making.

This release was published on openPR.